Cumberland Pharmaceuticals Agrees to Sell Branded Pharmaceutical Portfolio to Apotex for $100M
On April 23, 2026, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) agreed to sell its branded pharmaceutical portfolio to an affiliate of Apotex in a cash deal valued at $100 million. The transaction is subject to shareholder approval and will allow Cumberland to retain its pipeline and majority stake in Cumberland Emerging Technologies.
Tickers: $CPIX
Topics: Corporate Restructuring FDA Approval Pharmaceuticals